

Ashley E Rosko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/418925/publications.pdf>

Version: 2024-02-01

119
papers

1,356
citations

394421

19
h-index

414414

32
g-index

120
all docs

120
docs citations

120
times ranked

2027
citing authors

#	ARTICLE	IF	CITATIONS
1	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. <i>Blood Advances</i> , 2020, 4, 3528-3549.	5.2	113
2	NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1006-1019.	4.9	85
3	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 5946-5955.	7.0	72
4	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016, 136, 89-98.	2.4	68
5	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. <i>Journal of Geriatric Oncology</i> , 2019, 10, 479-485.	1.0	64
6	Multiple Myeloma in the Older Adult: Better Prospects, More Challenges. <i>Journal of Clinical Oncology</i> , 2014, 32, 2531-2540.	1.6	61
7	Ninety-minute daratumumab infusion is safe in multiple myeloma. <i>Leukemia</i> , 2018, 32, 2495-2518.	7.2	53
8	Incidence and survival of hematological cancers among adults ages ≥75 years. <i>Cancer Medicine</i> , 2018, 7, 3425-3433.	2.8	47
9	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.	4.1	46
10	T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 7-15.	2.0	37
11	Approach to the Older Adult With Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 500-518.	3.8	36
12	Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice. <i>BMC Geriatrics</i> , 2020, 20, 231.	2.7	36
13	Survivorship care for older adults with cancer: U13 conference report. <i>Journal of Geriatric Oncology</i> , 2016, 7, 305-312.	1.0	34
14	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 764-768.	1.0	26
15	Use of geriatric assessment in hematopoietic cell transplant. <i>Journal of Geriatric Oncology</i> , 2020, 11, 225-236.	1.0	25
16	Association of Prediagnostic Frailty, Change in Frailty Status, and Mortality After Cancer Diagnosis in the Women's Health Initiative. <i>JAMA Network Open</i> , 2020, 3, e2016747.	5.9	25
17	Advances in Management for Older Adults With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 2102-2114.	1.6	24
18	Ageing: Treating the Older Patient. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 193-200.	2.0	23

#	ARTICLE	IF	CITATIONS
19	Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 813-819.	1.0	23
20	Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment. <i>Journal of Leukemia (Los Angeles, Calif)</i> , 2014, 02, .	0.1	22
21	Frailty in Hematologic Malignancy. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 143-154.	2.3	22
22	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102) Tj ETQq0 0.4 rgBT /00erlock 10	0.4	20
23	Myeloma in Elderly Patients: When Less Is More and More Is More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 575-585.	3.8	20
24	Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2018, 53, 1418-1427.	2.4	19
25	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 294-302.	1.2	17
26	Myeloma in Elderly Patients: When Less Is More and More Is More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 575-585.	3.8	16
27	Multidisciplinary telemedicine and the importance of being seen. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1349-1351.	1.0	16
28	Prevalence of lifestyle behaviors and associations with health-related quality of life among older female cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 3049-3059.	2.2	15
29	AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. <i>Cancer Medicine</i> , 2021, 10, 965-973.	2.8	12
30	Pharmacokineticâ€¦Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€¦Dose Melphalan for Autologous Stem Cell Transplant. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 748-758.	2.5	11
31	The pharmacologic management of multiple myeloma in older adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 887-902.	1.8	11
32	Simplified frailty assessment tools: are we really capturing frailty or something else?. <i>Leukemia</i> , 2020, 34, 1967-1969.	7.2	11
33	First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 1838-1838.	1.4	11
34	A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. <i>Journal of Geriatric Oncology</i> , 2018, 9, 287-290.	1.0	10
35	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. <i>Blood</i> , 2019, 134, 602-602.	1.4	10
36	Vancomycin-resistant enterococci infection: not just for the transplanted. <i>Leukemia and Lymphoma</i> , 2014, 55, 1320-1325.	1.3	9

#	ARTICLE	IF	CITATIONS
37	Newly Diagnosed Myeloma in 2020. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e144-e158.	3.8	9
38	Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. Journal of Geriatric Oncology, 2021, 12, 235-238.	1.0	9
39	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1107-1115.	2.0	9
40	Let's get it on: Addressing sex and intimacy in older cancer survivors. Journal of Geriatric Oncology, 2021, 12, 312-315.	1.0	8
41	Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients. Frontiers in Oncology, 2020, 10, 575168.	2.8	8
42	Integration of a Geriatric Assessment With Intervention in the Care of Older Adults With Hematologic Malignancies. Frontiers in Oncology, 2021, 11, 775050.	2.8	8
43	Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. Cancers, 2022, 14, 2277.	3.7	8
44	Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look. Biology of Blood and Marrow Transplantation, 2020, 26, e198-e201.	2.0	7
45	Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation. Cancers, 2021, 13, 613.	3.7	7
46	Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. Journal of Geriatric Oncology, 2021, 12, 499-507.	1.0	7
47	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. Bone Marrow Transplantation, 2019, 54, 1553-1561.	2.4	6
48	AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes. Journal of Clinical Medicine, 2020, 9, 3778.	2.4	6
49	Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1027-1036.	4.9	6
50	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. Blood, 2018, 132, 123-123.	1.4	6
51	Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. Blood, 2019, 134, 4573-4573.	1.4	6
52	Preventing Acute Leukemia Relapse after Allogeneic Transplants: How to Move Forward?. Biology of Blood and Marrow Transplantation, 2013, 19, 2-3.	2.0	5
53	Heavy Lifting: Nomenclature and Novel Therapy for Gamma Heavy Chain Disease and Other Heavy Chain Disorders. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 493-498.	0.4	5
54	Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant. Frontiers in Oncology, 2022, 12, 801879.	2.8	5

#	ARTICLE	IF	CITATIONS
55	Treatment of older adult or frail patients with multiple myeloma. Hematology American Society of Hematology Education Program, 2021, 2021, 46-54.	2.5	5
56	Reprint of: Aging: Treating the Older Patient. Biology of Blood and Marrow Transplantation, 2017, 23, S10-S17.	2.0	4
57	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of Blood and Marrow Transplantation, 2020, 26, 44-49.	2.0	4
58	Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. Journal of Clinical Medicine, 2020, 9, 3626.	2.4	4
59	Transplant Physicians's Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. Biology of Blood and Marrow Transplantation, 2020, 26, S45-S46.	2.0	4
60	The Cancer and Aging Research Group (CARG) infrastructure: The clinical implementation core. Journal of Geriatric Oncology, 2021, 12, 1164-1165.	1.0	4
61	Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma. Blood, 2018, 132, 1933-1933.	1.4	4
62	Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant. Blood, 2018, 132, 3434-3434.	1.4	4
63	The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis. Blood, 2019, 134, 1833-1833.	1.4	4
64	Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients. Blood, 2015, 126, 1835-1835.	1.4	4
65	Bone Health and Survival in Women With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 597-602.e1.	0.4	3
66	Most multiple myeloma patients have low testosterone. Leukemia and Lymphoma, 2019, 60, 836-838.	1.3	3
67	Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected. Blood, 2016, 128, 2420-2420.	1.4	3
68	Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival. Transplantation and Cellular Therapy, 2021, 27, 337.e1-337.e7.	1.2	2
69	Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation. Journal of Clinical Medicine, 2021, 10, 2843.	2.4	2
70	Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL). Blood, 2019, 134, 2024-2024.	1.4	2
71	AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes. Blood, 2019, 134, 2029-2029.	1.4	2
72	T-Cell p16INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma. Blood, 2014, 124, 2023-2023.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. <i>Blood</i> , 2015, 126, 3200-3200.	1.4	2
74	Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-1.	1.4	2
75	Effect of Geriatric Assessment and Intervention on Overall Survival Among Older Adults with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 31-32.	1.4	2
76	Multidisciplinary Approach to Older Adults with Hematologic Malignanciesâ€”a Paradigm Shift. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 31-38.	2.3	2
77	Refining hematopoietic cell transplant: A concise review. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 266-267.	1.5	1
78	The Devil is in the Details: Confidentiality Challenges in the Age of Genetics. <i>HEC Forum</i> , 2015, 27, 79-86.	0.8	1
79	Levofloxacin Prophylaxis for Autologous Stem Cell Transplant: A Second Look. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S148.	2.0	1
80	AL Amyloidosis: The Prognostic Impact of Maintenance Therapy Following ASCT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S229-S230.	2.0	1
81	Exercise Is Medicine: Restoring Function in Older Adults with Hematologic Malignancy. <i>Blood</i> , 2018, 132, 4870-4870.	1.4	1
82	Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4549-4549.	1.4	1
83	A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3208-3208.	1.4	1
84	Falls in Older Adults with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4485-4485.	1.4	1
85	Pharmacist-Led Audits for Older Adults With Cancer Yield Significant Interventions. <i>Innovation in Aging</i> , 2020, 4, 208-208.	0.1	1
86	Evaluating the Carg Chemotherapy Toxicity Calculator Among Older Adults Newly Diagnosed with Hematologic Malignancy. <i>Blood</i> , 2021, 138, 1931-1931.	1.4	1
87	Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 3796-3796.	1.4	1
88	Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant. <i>Blood</i> , 2020, 136, 17-18.	1.4	1
89	Peripheral blood <sc>CD3</sc> ⁺ Tâ€cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies. <i>British Journal of Haematology</i> , 0, , .	2.5	1
90	Salvage chemotherapy and autologous hematopoietic cell transplant in primary refractory diffuse large B-cell lymphoma: progress or better patient selection?. <i>Leukemia and Lymphoma</i> , 2012, 53, 756-757.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Post-Transplant Discharge to Rehabilitation Facility Is Associated with Increased All-Cause and Non-Relapse Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S153.	2.0	0
92	A story of connection: A tribute to Arti Hurria, MD. <i>Journal of Geriatric Oncology</i> , 2020, 11, 164-165.	1.0	0
93	Overcoming the Effect of Racial Disparities in Multiple Myeloma (MM) with Autologous Stem Cell Transplant (ASCT). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S235-S236.	2.0	0
94	Continued Improvement in Survival of Multiple Myeloma Patients: An Institutional Study from 1992-2016. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S225-S226.	2.0	0
95	Not So Fast: Geriatric Syndromes Can Be Identified and Intervened upon Prior to Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S116.	2.0	0
96	BEP Versus BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Relapsed Lymphoma. A Single Center Retrospective Review of Two Contemporaneous Cohorts. <i>Blood</i> , 2011, 118, 2019-2019.	1.4	0
97	Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival. <i>Blood</i> , 2016, 128, 4444-4444.	1.4	0
98	Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3409-3409.	1.4	0
99	Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 1241-1241.	1.4	0
100	Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3410-3410.	1.4	0
101	Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation. <i>Blood</i> , 2018, 132, 3357-3357.	1.4	0
102	Restoring Functional Deficits in Older Adults with Hematologic Malignancy. <i>Blood</i> , 2019, 134, 4776-4776.	1.4	0
103	Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 5501-5501.	1.4	0
104	Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. <i>Blood</i> , 2019, 134, 5819-5819.	1.4	0
105	Multiple Myeloma in Older Adults. , 2020, , 549-565.		0
106	Lifestyle Challenges Among Older Female Cancer Survivors. <i>Innovation in Aging</i> , 2020, 4, 479-479.	0.1	0
107	Lenalidomide (len) Maintenance (maint) after Autologous Stem Cell Transplant (ASCT) for Multiple Mmyeloma (MM) Improves Outcomes of Patients (pts) with Both Standard- and High-Risk Cytogenetics: A Single Institutional Experience of over 1000 ASCT Pts.. <i>Biology of Blood and Marrow Transplantation</i> . 2020. 26. S234.	2.0	0
108	Interval Progression Serves As a Predictor of Adverse Outcomes in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3940-3940.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias. <i>Blood</i> , 2021, 138, 2449-2449.	1.4	0
110	Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 3933-3933.	1.4	0
111	Improvement in Survival of AML and MDS Patients Following Allogeneic Transplant: A Long-Term Institutional Experience. <i>Blood</i> , 2020, 136, 30-30.	1.4	0
112	Survival Implications of Opioid Use after Blood and Marrow Transplantation. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
113	Comparison of Bone Marrow Versus Peripheral Blood in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide- a Retrospective Analysis. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
114	Trend in Survival in Patients Undergoing Allogeneic Stem Cell Transplantation: An Institutional Experience. <i>Blood</i> , 2020, 136, 15-15.	1.4	0
115	Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality. <i>Blood</i> , 2020, 136, 42-42.	1.4	0
116	Pre-Transplant Geriatric Assessment (GA) with Intervention Among Allogeneic Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S442-S443.	1.2	0
117	Allogeneic Transplantation in Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S115-S116.	1.2	0
118	Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT).. , 2019, 2, 12-18.		0
119	Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. <i>Frontiers in Oncology</i> , 2022, 12, 858426.	2.8	0